Later studies with advanced prostate cancer patients have shown that Bicalutamide combined with an LHRH agonist resulted in improved PSA levels and overall survival compared to LHRH agonist treatment alone (39, 40). The gene discussed is KLK3; the disease is prostate carcinoma.